Analysts Pivot on Banks, Biotech, and Big Tech

UBS ran a parallel sweep through life sciences and industrials.

• TMO — UBS to Buy, PT $730 (21% upside from $603)
• ILMN — UBS to Buy, PT $260 from $135 (23% upside)
• WAT — UBS to Buy, PT $490 from $375 (+31%)
• ETN — UBS to Buy, PT $515 (14% above current price)
• ECHO — UBS to Buy, PT $150 from $127 (67% implied upside)

JP Morgan backed transport and equipment names.

• CHRW — Citigroup to Buy, PT $185 from $196 (25% upside)
• ODFL — Citigroup to Buy, PT $223 from $231 (20% upside)
• HRI — JP Morgan to Overweight, PT $175 from $165 (21% upside)
• META — JP Morgan to Overweight, PT $820 from $640, citing AI infrastructure

Other notable upgrades:

• LMT — UBS to Buy, PT $674 from $581 (28% implied upside); stock had fallen 11% in a month
• INTC — Northland to Outperform, PT $120 (25% above $95.80), citing foundry recovery
• SNPS — Morgan Stanley to Overweight (PT $500); Wells Fargo also to Overweight (PT $475) the following session
• ABNB — Raymond James to Outperform, PT $200; stock up 21% in one month
• MLM — Wells Fargo to Overweight, PT $609 (19% upside)
• PCAR — RBC Capital to Outperform, PT $150 from $130 (23% upside)
• SG — Keybanc to Overweight, PT $9
• ABG — Seaport Global to Buy, PT $300 (38% implied upside)
• MGY — JP Morgan to Overweight, PT $33 from $32
• ST — Barclays to Overweight, PT $55; stock up 5% on the week
• FDS — William Blair to Outperform
• YUM — Wells Fargo to Overweight, PT $175
• CAT — Freedom Broker to Buy, PT $980 from Hold
• KYMR — Wolfe Research to Outperform; SI at 14.8% of FF
• UGI — Jefferies to Buy, PT $43 from $40
• SMMT — Jefferies to Buy, PT $25 from $15 (+67%)
• SGMT — Barclays to Overweight, PT $18 from $8 (68% implied upside)
• CPRT — Barrington to Outperform, PT $40
• IESC — Freedom Broker to Buy, PT $440; stock down 57% this month
• NVS — HSBC to Hold, PT $136 from $123
• FIGR — BofA to Neutral, PT $49 from $31 (+58%)
• XYZ — StoneX to Buy, PT $105 (32% upside)
• MGY — JP Morgan to Overweight
• CHRW — Citigroup upgrade noted above

Downgrades

Morgan Stanley cut several regional bank names in the same sweep that produced its upgrades.

• OZK — Morgan Stanley to Underweight, PT $56; SI at 13.7% of FF
• CUBI — Morgan Stanley to Underweight, PT $89
• PB — Morgan Stanley to Underweight, PT $80
• SFNC — Morgan Stanley to Underweight, PT $26 (subsequently upgraded by KBW)
• ZION — Morgan Stanley to Underweight from Overweight, PT $77; SI had fallen 33.5% in a month
• CBC — Morgan Stanley downgrade, stock at $32.64

BMO Capital trimmed two healthcare names.

• AMGN — BMO to Market Perform, PT $450; HSBC also cut to Hold (PT $425 from $445)
• BNTX — BMO to Market Perform from Outperform, PT $105 from $128 (-18%)

UBS cut two life sciences names in its sector review.

• MTD — UBS to Neutral from Buy, PT $1,460 (-12%)
• RVTY — UBS to Neutral from Buy, PT $140 from $120

Wells Fargo cut construction materials.

• VMC — Wells Fargo to Underweight, PT $254 from $305 (-17%)
• EXP — Wells Fargo to Equal-Weight, PT $196 from $231

JP Morgan turned cautious on several names.

• URI — JP Morgan to Neutral from Overweight, PT $1,170 from $1,235
• CHWY — JP Morgan to Neutral, PT $24 (-17%); Evercore ISI had already cut to In-Line ($25) after an earnings miss
• GPOR — JP Morgan to Underweight, target cut 19%
• ATO — JP Morgan to Neutral, PT $180 from $198

Other notable downgrades.

• NVO — Morgan Stanley to Underweight on GLP-1 competition; stock down 7.8% in a month
• PTON — Morgan Stanley to Underweight, PT $4.50 from $5.00; SI at 14% of FF
• BHVN — RBC to Sector Perform, PT $19 from $23; SI at 13.4% of FF
• BCRX — RBC to Sector Perform, PT $11 from $13
• SMR — UBS to Sell, PT $6 from $10 (-40%); SI at 23.1% of FF
• COO — Bank of America and Baird both cut to Hold; targets $65 and $61; stock fell 6.2% intraday
• ACVA — Needham to Hold from Buy; Barrington added Underperform the next day. SI hit a four-week high at 9% of FF
• ESS — Mizuho to Neutral, PT $295 from $308
• BBY — DA Davidson to Neutral, PT $95; SI at 6.8% of FF, down 19% in a month
• ALV — TD Cowen to Hold, PT $137
• DOCS — Freedom Capital to Hold, PT raised to $27 from $24
• PHR — Raymond James to Market Perform; stock down 10% in a week
• WLK — BMO to Market Perform, PT $82 from $96 (-14.6%)
• AU — BMO to Market Perform, PT $115
• BOW — Citizens to Market Perform

Initiations

• BIRK — BMO Capital initiates at Market Perform, PT $35; stock at $32.62

Sector Themes

Financials: Divergent Calls on Regional Banks

Morgan Stanley ran the week's most concentrated sector action. The firm upgraded select regional banks — MTB, EWBC, CFR, CBSH — while simultaneously downgrading OZK, CUBI, ZION, PB, and SFNC to Underweight. The signal is clear: the firm is rotating conviction within the group, not making a blanket sector call.

Life Sciences: UBS Reshuffles Coverage

UBS made the largest single-firm move in life sciences. TMO, ILMN, and WAT all received Buy upgrades with target increases above 20%. MTD and RVTY were cut to Neutral in the same sweep. Analyst Doug Schenkel drove most of the action.

Biotech: Bears Hold the Edge

Multiple biotech names drew downgrades this week. BNTX, BHVN, BCRX, and NVO were all cut. AMGN was downgraded by two separate firms — BMO and HSBC — in two days. KYMR was the lone clear upgrade in the space.

Transport and Freight: Citigroup and JP Morgan Split

Citigroup upgraded both CHRW and ODFL, seeing value at current prices despite lower targets. JP Morgan moved the other way on URI, cutting to Neutral. The divergence reflects ongoing debate over freight cycle timing.

Tech and Semiconductors: AI Names Stay Favoured

META received a significant JP Morgan upgrade, with the target jumping 28% to $820. INTC got a bullish call from Northland. SNPS attracted upgrades from both Morgan Stanley and Wells Fargo in the same week. Broad software weakness did not deter analysts from adding conviction on select names.